Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback